Call From Laminitis Researchers to Participate in Study

If your horse has been treated with an SGLT2 inhibitor (Ertugliflozin, Canagliflozin, Dapagliflozin or similar), they might be eligible to participate in a new study.
Share
Favorite
Close

No account yet? Register

ADVERTISEMENT

If your horse has been treated with an SGLT2 inhibitor (Ertugliflozin, Canagliflozin, Dapagliflozin or similar), they might be eligible to participate in a new study. 

SGLT2i are human antidiabetic medications that are prescribed with increasing frequency to horses to treat and prevent laminitis associated with high insulin concentrations. However, there is limited data on the long-term effects of these medications in horses.  

Murdoch University in Western Australia is conducting a study to document owner satisfaction and side-effects in horses and ponies treated with SGLT2 inhibitors.

The online survey takes 5 minutes to complete, and your responses will allow researchers to collect data to better understand the use of SGLT2 inhibitors in horses. Your experiences will help direct future research to improve the welfare of laminitic horses and ponies. All surveys are completely anonymous.   

This research has human ethics approval from Murdoch University (Permit 2023/057). 

For queries, please contact Dr Gabriele Rossi (g.rossi@murdoch.edu.au). 

SURVEY LINK: https://murdochuni.syd1.qualtrics.com/jfe/form/SV_2u81cwaM6XxK6yO 

Share
Favorite
Close

No account yet? Register

Written by:

Product and information releases by various organizations and companies.

Leave a Reply

Related Articles

Stay on top of the most recent Horse Health news with

FREE weekly newsletters from TheHorse.com

Sponsored Content

Weekly Poll

sponsored by:

What lameness issues has your horse experienced? Select all that apply.
192 votes · 380 answers

Readers’ Most Popular

Sign In

Don’t have an account? Register for a FREE account here.

Need to update your account?

You need to be logged in to fill out this form

Create a free account with TheHorse.com!